Literature DB >> 34192183

Presentation of newly diagnosed type 1 diabetes in children and young people during COVID-19: a national UK survey.

Sze May Ng1,2, Katherine Woodger1, Fiona Regan3, Astha Soni4, Neil Wright5, Juliana Chizo Agwu6, Eleri Williams7, Alison Timmis8, Melanie Kershaw9, Christopher Moudiotis10, Josephine Drew11.   

Abstract

In the UK, there have been reports of significant reductions in paediatric emergency attendances and visits to the general practitioners due to COVID-19. A national survey undertaken by the UK Association of Children's Diabetes Clinicians found that the proportion of new-onset type 1 diabetes (T1D) presenting with diabetes ketoacidosis (DKA) during this COVID-19 pandemic was higher than previously reported, and there has been an increase in presentation of severe DKA at diagnosis in children and young people under the age of 18 years. Delayed presentations of T1D have been documented in up 20% of units with reasons for delayed presentation ranging from fear of contracting COVID-19 to an inability to contact or access a medical provider for timely evaluation. Public health awareness and diabetes education should be disseminated to healthcare providers on the timeliness of referrals of children with T1D. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  endocrinology; epidemiology; health services research

Year:  2020        PMID: 34192183      PMCID: PMC7607512          DOI: 10.1136/bmjpo-2020-000884

Source DB:  PubMed          Journal:  BMJ Paediatr Open        ISSN: 2399-9772


Diabetes is a significant cause of morbidity and mortality in patients with COVID-19. The recent national diabetes and mortality data in England reported that adults with type 1 diabetes (T1D) had 3.5 times the odds respectively of dying in hospital with COVID-19 compared with those without diabetes.1 In the UK, there have been reports of significant reductions in paediatric emergency attendances due to COVID-19. The national survey undertaken by the UK Association of Children’s Diabetes Clinicians aims to review the impact of COVID-19 on diabetes ketoacidosis (DKA) presentations across the country. All diabetes units caring for children and young people (CYP) in England, Wales, Scotland and Northern Ireland and those submitting data to the National Paediatric Diabetes Audit (NPDA) were invited to complete a questionnaire (via Google Forms) relating to history given to the clinical teams of presentation T1D between 1 March 2020 to 30 June 2020. Responses were received from 88 units, 76 from England, 10 from Wales and 2 from Northern Ireland (table 1).
Table 1

Response to the questionnaire on newly diagnosed type 1 diabetes in children or young people and diabetes ketoacidosis (DKA) presentations

Number of units returning surveyNewly diagnosed type 1 diabetes children or young peopleDKA presentationsSevere presentations of DKA (pH <7.1)DeathsDelayed presentations due to COVID-19
RegionsTotal numberTotal number (mean)Total number(% of new presentations)Total number(% of new presentations)Total number(% of new presentations)Total number(% of new presentations)
England76399 (5.2)205 (52)108 (27)0 (0)82 (20)
Wales1035 (3.5)19 (54)12 (34)0 (0)5 (14)
Northern Ireland216 (8.0)7 (44)4 (25)0 (0)2 (13)
Total88450231 (51)124 (28)0 (0)89 (20)
Response to the questionnaire on newly diagnosed type 1 diabetes in children or young people and diabetes ketoacidosis (DKA) presentations The survey showed that 450 CYP were newly diagnosed with T1D between 1 March 2020 and 30 June 2020. The majority of centres (84%) had at least one patient admitted as newly diagnosed T1D (mean: five cases per unit, range: 0–30). Eighty-eight per cent of centres had 1–10 DKA admissions with 71% having 1–10 severe DKA cases. Of all patients presenting as newly diagnosed T1D, 51% presented in DKA and 54% of presented with severe DKA (defined as pH <7.1). During this time period, no children with T1D died as a result of DKA. In all units, 20% of newly diagnosed T1D were reported to have had a delayed presentation due to COVID-19. The reasons for delayed reporting of presentation were grouped into themes (table 2). Fear of COVID-19 was reported in 40% of cases. Issues regarding the inability to access GP services as well as limited GP services with no face-to-face reviews were reported in 22% of cases, while 7% had issues accessing secondary care units due to advice not to attend by NHS111 or the general practice (GP). Finally, 17% of cases reported a delayed presentation due to symptoms being misdiagnosed or not recognised as diabetes such as: symptoms mistaken for a respiratory illness during a GP video consultation, tiredness due to lack of routine and increased thirst attributed to a ‘heat wave’ by the family.
Table 2

Reasons for delayed presentations

Fear of COVID-19, %Inability to access GP or limited GP service, %Inability or discouraged to attend hospital A&E or inpatient unit after contacting NHS111, %Symptoms misdiagnosed or not recognised as diabetes, %
England3622513
Wales3014
Northern Ireland1010
Total4022717

A&E, Accident and Emergency.

Reasons for delayed presentations A&E, Accident and Emergency. While in non-COVID-19 times, there would be still be delays in presentation; the proportion of new onset T1D in CYP under 18 years presenting in DKA (51%) during this COVID-19 period was higher than previously reported of 38% in the UK around the same time period.2 While in comparison, the percentage of DKA in newly diagnosed cases prior to COVID-19 had remained constant over 10 years at 26.3% in Germany.3 4 The proportion of those in DKA presenting as severe DKA was high at 54%, while the 2017, NPDA reported that 26% of newly diagnosed presented in DKA, but no data were available for those presenting in severe DKA.5 Increases in DKA and severe DKA at diagnosis in children during the COVID-19 pandemic were reported in Germany, and delayed access of care provisions have been reported globally.4 In our report, delayed presentation has been documented in 20% of units. Reasons for delayed presentation have ranged from fear of contracting COVID-19 to an inability to contact access a medical provider for timely evaluation. Limitations from this report was reliance on professional’s recall as to the number of presentations delayed due to COVID-19 and the reasons for their delay. The global epidemiological and clinical patterns of COVID-19 among children with diabetes are still very limited. Further emphasis should be made on the dissemination of education to healthcare providers regarding the timeliness of referrals of children with T1D.
  11 in total

1.  COVID-19 and diabetes in children.

Authors:  Sara Prosperi; Francesco Chiarelli
Journal:  Ann Pediatr Endocrinol Metab       Date:  2022-09-30

2. 

Authors:  Ellen B Goldbloom; Melanie Buba; Maala Bhatt; Sinthuja Suntharalingam; W James King
Journal:  Paediatr Child Health       Date:  2022-09-08       Impact factor: 2.600

3.  Innovative virtual care delivery in a Canadian paediatric tertiary-care centre.

Authors:  Ellen B Goldbloom; Melanie Buba; Maala Bhatt; Sinthuja Suntharalingam; W James King
Journal:  Paediatr Child Health       Date:  2022-05-06       Impact factor: 2.600

4.  The Silent Epidemic of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Children and Adolescents in Italy During the COVID-19 Pandemic in 2020.

Authors:  Valentino Cherubini; Monica Marino; Andrea E Scaramuzza; Valentina Tiberi; Adriana Bobbio; Maurizio Delvecchio; Elvira Piccinno; Federica Ortolani; Stefania Innaurato; Barbara Felappi; Francesco Gallo; Carlo Ripoli; Maria Rossella Ricciardi; Filomena Pascarella; Filomena A Stamati; Felice Citriniti; Claudia Arnaldi; Sara Monti; Vanna Graziani; Fiorella De Berardinis; Cosimo Giannini; Francesco Chiarelli; Maria Zampolli; Rosaria De Marco; Giulia Patrizia Bracciolini; Caterina Grosso; Valeria De Donno; Barbara Piccini; Sonia Toni; Susanna Coccioli; Giuliana Cardinale; Marta Bassi; Nicola Minuto; Giuseppe D'Annunzio; Claudio Maffeis; Marco Marigliano; Angela Zanfardino; Dario Iafusco; Assunta S Rollato; Alessia Piscopo; Stefano Curto; Fortunato Lombardo; Bruno Bombaci; Silvia Sordelli; Chiara Mameli; Maddalena Macedoni; Andrea Rigamonti; Riccardo Bonfanti; Giulio Frontino; Barbara Predieri; Patrizia Bruzzi; Enza Mozzillo; Francesco Rosanio; Adriana Franzese; Gavina Piredda; Francesca Cardella; Brunella Iovane; Valeria Calcaterra; Maria Giulia Berioli; Anna Lasagni; Valentina Pampanini; Patrizia Ippolita Patera; Riccardo Schiaffini; Irene Rutigliano; Gianfranco Meloni; Luisa De Sanctis; Davide Tinti; Michela Trada; Lucia Paola Guerraggio; Roberto Franceschi; Vittoria Cauvin; Gianluca Tornese; Francesca Franco; Gianluca Musolino; Giulio Maltoni; Valentina Talarico; Antonio Iannilli; Lorenzo Lenzi; Maria Cristina Matteoli; Erica Pozzi; Carlo Moretti; Stefano Zucchini; Ivana Rabbone; Rosaria Gesuita
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

5.  Organisation of care in paediatric intensive care units during the first 18 months of the COVID-19 pandemic: a scoping review protocol.

Authors:  Katie Hill; Catherine McCabe; Maria Brenner
Journal:  BMJ Open       Date:  2022-05-25       Impact factor: 3.006

6.  Alarming Increase of Ketoacidosis Prevalence at Type 1 Diabetes-Onset in Austria-Results From a Nationwide Registry.

Authors:  Katrin Nagl; Thomas Waldhör; Sabine E Hofer; Maria Fritsch; Dagmar Meraner; Christine Prchla; Birgit Rami-Merhar; Elke Fröhlich-Reiterer
Journal:  Front Pediatr       Date:  2022-02-14       Impact factor: 3.418

7.  Multicentre service evaluation of presentation of newly diagnosed cancers and type 1 diabetes in children in the UK during the COVID-19 pandemic.

Authors:  Gemma Williams; Ross McLean; Jo-Fen Liu; Timothy A Ritzmann; Madhumita Dandapani; Dhurgshaarna Shanmugavadivel; Pooja Sachdev; Mark Brougham; Rod T Mitchell; Nicholas T Conway; James Law; Alice Cunnington; Gbemi Ogunnaike; Karen Brougham; Elizabeth Bayman; David Walker
Journal:  BMJ Paediatr Open       Date:  2021-11-11

8.  Peculiar characteristics of new-onset Type 1 Diabetes during COVID-19 pandemic.

Authors:  Concetta Mastromauro; Annalisa Blasetti; Marina Primavera; Lucio Ceglie; Angelika Mohn; Francesco Chiarelli; Cosimo Giannini
Journal:  Ital J Pediatr       Date:  2022-02-09       Impact factor: 2.638

9.  Trends in Type 1 Diabetic Ketoacidosis During COVID-19 Surges at 7 US Centers: Highest Burden on non-Hispanic Black Patients.

Authors:  Andrew R Lavik; Osagie Ebekozien; Nudrat Noor; G Todd Alonso; Sarit Polsky; Scott M Blackman; Justin Chen; Sarah D Corathers; Carla Demeterco-Berggren; Mary Pat Gallagher; Margaret Greenfield; Ashley Garrity; Saketh Rompicherla; Robert Rapaport; Nana-Hawa Yayah Jones
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

10.  COVID-19 in two children with new-onset diabetes: case reports.

Authors:  Ana Lança; Cláudia Rodrigues; Catarina Diamantino; Ana Laura Fitas
Journal:  BMJ Case Rep       Date:  2022-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.